Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
暂无分享,去创建一个
Winfried Brenner | Norbert Avril | Nadia Harbeck | Markus Schwaiger | Sven Mahner | W. Brenner | S. Sassen | M. Schwaiger | N. Harbeck | R. Tiling | S. Kahlert | M. Untch | N. Avril | A. Lebeau | S. Mahner | Michael Untch | Stefanie Sassen | Reinhold Tiling | Annette Lebeau | Jörg Schwarz-Dose | Steffen Kahlert | Fritz Jaenicke | F. Jaenicke | Jörg Schwarz-Dose
[1] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Wolfgang A Weber,et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Wolfgang A Weber,et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. , 2007, The Lancet. Oncology.
[5] D. Mankoff,et al. Serial 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP) , 2007, Breast Cancer Research and Treatment.
[6] J. Bryant,et al. Pathobiology of preoperative chemotherapy , 2002 .
[7] G. Hortobagyi,et al. Pathological assessment of response to induction chemotherapy in breast cancer. , 1986, Cancer research.
[8] C. V. D. van de Velde,et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Wolfgang A Weber,et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P F Sharp,et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Ludovic Ferrer,et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Bryant,et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. , 2002, Cancer.
[14] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Larson,et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[18] L. Mortelmans,et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Giordano,et al. Update on locally advanced breast cancer. , 2003, The oncologist.
[20] G. Hortobagyi,et al. Update on the management of inflammatory breast cancer. , 2003, The oncologist.
[21] Paul E Kinahan,et al. Dynamic and Static Approaches to Quantifying 18F-FDG Uptake for Measuring Cancer Response to Therapy, Including the Effect of Granulocyte CSF , 2007, Journal of Nuclear Medicine.
[22] J. Blohmer,et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Fiona J. Gilbert,et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET , 2007, Breast Cancer Research and Treatment.
[25] G. Hortobagyi,et al. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Michael Bader,et al. Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] J. Nährig,et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Mark Muzi,et al. 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[29] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] G. Giaccone,et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. , 1998, British Journal of Cancer.
[32] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] F. Penault-Llorca,et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.
[34] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] I. Zuna,et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] D. Mankoff,et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] T. Turkington,et al. Clinical applications of PET in oncology. , 2004, Radiology.